Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers

被引:51
作者
Veeraraghavan, Harini [1 ]
Friedman, Claire F. [2 ,6 ]
DeLair, Deborah F. [3 ,7 ]
Nincevic, Josip [4 ,8 ]
Himoto, Yuki [4 ,9 ]
Bruni, Silvio G. [4 ,10 ]
Cappello, Giovanni [4 ,11 ]
Petkovska, Iva [4 ]
Nougaret, Stephanie [4 ,12 ,13 ]
Nikolovski, Ines [4 ]
Zehir, Ahmet [3 ]
Abu-Rustum, Nadeem R. [5 ]
Aghajanian, Carol [2 ,6 ]
Zamarin, Dmitriy [2 ,6 ]
Cadoo, Karen A. [2 ,6 ]
Diaz, Luis A., Jr. [2 ,6 ]
Leitao, Mario M., Jr. [5 ]
Makker, Vicky [2 ,6 ]
Soslow, Robert A. [3 ]
Mueller, Jennifer J. [5 ]
Weigelt, Britta [3 ]
Lakhman, Yulia [4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, Body Imaging Serv, 1275 York Ave, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10021 USA
[6] Weill Cornell Med Coll, Dept Med, New York, NY USA
[7] NYU, Dept Pathol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
[8] Sisters Charity Hosp, Dept Radiol, Zagreb, Croatia
[9] Japanese Red Cross Wakayama Med Ctr, Dept Diagnost Radiol, Wakayama, Japan
[10] Trillium Hlth Partners, Dept Radiol, Mississauga, ON, Canada
[11] FPO IRCCS, Dept Radiol, Candiolo Canc Inst, Turin, Italy
[12] INSERM U1194, Inst Canc Res Montpellier IRCM, Dept Radiol, Montpellier, France
[13] Univ Montpellier, Montpellier Canc Inst, Dept Radiol, Montpellier, France
基金
日本学术振兴会;
关键词
PHASE-II TRIAL; REGULARIZATION PATHS; CARCINOMA; CLASSIFICATION; LANDSCAPE; DIAGNOSIS; SELECTION;
D O I
10.1038/s41598-020-72475-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor mutational burden-high (TMB-H) endometrial cancers (ECs). Patients who underwent targeted massively parallel sequencing of primary ECs between 2014 and 2018 and preoperative CE-CT were included (n=150). Molecular subtypes of EC were assigned using DNA polymerase epsilon (POLE) hotspot mutations and immunohistochemistry-based p53 and MMR protein expression. TMB was derived from sequencing, with >15.5 mutations-per-megabase as a cut-point to define TMB-H tumors. After radiomic feature extraction and selection, radiomic features and clinical variables were processed with the recursive feature elimination random forest classifier. Classification models constructed using the training dataset (n=105) were then validated on the holdout test dataset (n=45). Integrated radiomic-clinical classification distinguished MMR-D from copy number (CN)-low-like and CN-high-like ECs with an area under the receiver operating characteristic curve (AUROC) of 0.78 (95% CI 0.58-0.91). The model further differentiated TMB-H from TMB-low (TMB-L) tumors with an AUROC of 0.87 (95% CI 0.73-0.95). Peritumoral-rim radiomic features were most relevant to both classifications (p <= 0.044). Radiomic analysis achieved moderate accuracy in identifying MMR-D and TMB-H ECs directly from CE-CT. Radiomics may provide an adjunct tool to molecular profiling, especially given its potential advantage in the setting of intratumor heterogeneity.
引用
收藏
页数:10
相关论文
共 66 条
  • [51] Endometrial carcinomas with ambiguous features
    Soslow, Robert A.
    [J]. SEMINARS IN DIAGNOSTIC PATHOLOGY, 2010, 27 (04) : 261 - 273
  • [52] A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
    Sun, Roger
    Limkin, Elaine Johanna
    Vakalopoulou, Maria
    Dercle, Laurent
    Champiat, Stephane
    Han, Shan Rong
    Verlingue, Loic
    Brandao, David
    Lancia, Andrea
    Ammari, Samy
    Hollebecque, Antoine
    Scoazec, Jean-Yves
    Marabelle, Aurelien
    Massard, Christophe
    Soria, Jean-Charles
    Robert, Charlotte
    Paragios, Nikos
    Deutsch, Eric
    Ferte, Charles
    [J]. LANCET ONCOLOGY, 2018, 19 (09) : 1180 - 1191
  • [53] Breast Cancer Molecular Subtype Classifier That Incorporates MRI Features
    Sutton, Elizabeth J.
    Dashevsky, Brittany Z.
    Oh, Jung Hun
    Veeraraghavan, Harini
    Apte, Aditya P.
    Thakur, Sunitha B.
    Morris, Elizabeth A.
    Deasy, Joseph O.
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2016, 44 (01) : 122 - 129
  • [54] Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors
    Ta, Robert M.
    Hecht, Jonathan L.
    Lin, Douglas I.
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 401 - 406
  • [55] A clinically applicable molecular-based classification for endometrial cancers
    Talhouk, A.
    McConechy, M. K.
    Leung, S.
    Li-Chang, H. H.
    Kwon, J. S.
    Melnyk, N.
    Yang, W.
    Senz, J.
    Boyd, N.
    Karnezis, A. N.
    Huntsman, D. G.
    Gilks, C. B.
    McAlpine, J. N.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 113 (02) : 299 - 310
  • [56] PHASE-II TRIAL OF CISPLATIN AS 1ST-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    THIGPEN, JT
    BLESSING, JA
    HOMESLEY, H
    CREASMAN, WT
    SUTTON, G
    [J]. GYNECOLOGIC ONCOLOGY, 1989, 33 (01) : 68 - 70
  • [57] THIGPEN JT, 1979, CANCER TREAT REP, V63, P21
  • [58] Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
    Trebeschi, S.
    Drago, S. G.
    Birkbak, N. J.
    Kurilova, I
    Calin, A. M.
    Pizzi, A. Delli
    Lalezari, F.
    Lambregts, D. M. J.
    Rohaan, M. W.
    Parmar, C.
    Rozeman, E. A.
    Hartemink, K. J.
    Swanton, C.
    Haanen, J. B. A. G.
    Blank, C. U.
    Smit, E. F.
    Beets-Tan, R. G. H.
    Aerts, H. J. W. L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (06) : 998 - 1004
  • [59] Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
    Wang, Feng
    Zhao, Qi
    Wang, Ying-Nan
    Jin, Ying
    He, Ming-Ming
    Liu, Ze-Xian
    Xu, Rui-Hua
    [J]. JAMA ONCOLOGY, 2019, 5 (10) : 1504 - 1506
  • [60] Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature
    Wang, Xiaoxiao
    Kong, Cheng
    Xu, Weizhang
    Yang, Sheng
    Shi, Dan
    Zhang, Jingyuan
    Du, Mulong
    Wang, Siwei
    Bai, Yongkang
    Zhang, Te
    Chen, Zeng
    Ma, Zhifei
    Wang, Jie
    Dong, Gaochao
    Sun, Mengting
    Yin, Rong
    Chen, Feng
    [J]. THORACIC CANCER, 2019, 10 (10) : 1904 - 1912